Value in Health

Article	Citations
Author Reply	651
Editorial Board	559
EPH168 A Descriptive Epidemiological Study of Pediatric Sleep Medications in Japan: A Health Insurance Claims-Based Analysis	121
EPH249 Epidemiology of Patients With Thymic Carcinoma in the United States: A Systematic Literature Review	103
EPH282 3-Year Healthcare Resource Consumptions of Patients With Immunoglobulin A Nephropathy in a Large Real-World Italian Database	95
EPH9 Influence of Front Nutritional Labeling on Consumer Choices Related to Ultra-Processed Foods: Scoping Review	87
HTA64 Leveraging Machine Learning for Predicting Health Technology Assessment Outcomes	70
EPH288 Characteristics of NASH Patients Who Develop Hepatocellular Carcinoma (HCC) With and Without a Corresponding Cirrhosis Diagnosis	67
EPH80 Impact of the COVID-19 Pandemic on Arterial Hypertension Monitoring and Control in Portugal	64
EPH48 Impact of Influenza-like Illness on Health-Related Quality of Life in Japanese Adults	64
HPR15 Innovative Rebate Management in Oncology Drug Budgets: Streamlining Operations and Enhancing Financial Efficiency Through Technology in Newfoundland and Labrador's Cancer Care Program	61
HTA170 Use of Off-Label Comparators in Health Technonology Assessment in Portugal: A Review of Reimbursement Appraisal Reports	57
HPR7 The Discrepancy in Real-World Evidence of New Drug Expenditure Between Actual and Estimated Figures From Manufacturers and Government Agencies in Taiwan	56
HPR78 Opportunities and Barriers for the Implementation of the Personalized Medicine in Lithuania	55
EPH147 Situational Analysis of Sexual Health in Cartagena and Bolívar, Colombia 2023	55
HPR97 More Public Funding? A Choice Experiment on the Healthcare Funding System for Older Populations	55
EPH187 Contextualizing the Impact of Multiple Sclerosis (MS) in England Through HES Analysis	51
HPR225 Impact of the 2021 US Federal X-Waiver Practice Guideline Change on the Prescribing of Buprenorphine and Naltrexone for Treating Opioid Use Disorder in Medicaid Population	50
HTA310 Are Global Health Technology Assessment (HTA) Processes Inclusive and Equitable? A Scoping Review	50
HTA368 Do We Need to Adapt Our Health Technology Assessment (HTA) Systematic Literature Review (SLR) Methods to Comply With the New Joint Clinical Assessment (JCA) SLR Requirements?	47
When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations	47
Rare Diseases: Economic Evaluation and Policy Considerations	45
MSR105 Tackling Rare Events in Network Meta-Analysis: Comparative Performance of Methods for Sparse Safety Outcomes	43
MSR118 Integrating Large Language Models Into an Existing Review Process: Promises and Pitfalls	42
HPR16 Performance Indicators for the Assessment of Ageing-in-Place Reform Policies: A Scoping Review and Evidence Map	42

HTA86 Indirect Comparisons and Network Meta-Analysis in Spanish Drug Positioning Reports for Price and Financing	42
HPR87 Poland's Medical Fund Act: Progress of the New Fast-Track TLI Reimbursement Pathway	40
HTA78 Health Technology Assessment (HTA) Key Drivers for Oral Oncology Products: Comparison Between Brazil and European Countries	39
MSR42 Time to Stop Sinking Resources Into Developing Predictive Models That Yield No Value: A Framework and Opportunities for Health Economic Methods Development to Reduce Waste in Prediction Model De	38
HPR215 Exploring the Efficacy, Safety, and Regulatory Approval of Priority Reviewed Innovative Drugs in China (2015-2023)	38
HTA131 Opportunities for Patient Involvement in HTA in the Philippines: Lessons From Guidelines in Europe, North America, and the Asia-Pacific	38
HPR185 Performance-Based vs Finance-Based Managed Entry Agreements (MEAs): Global Trends and Challenges	38
MSR50 Use of a Fine-Tuned, Clinical, Bidirectional Transformer (BERT) Large Language Model (LLM) to Classify the Patient and Caregiver Voice Through Their Social Media Health Posts: An Example in Non-	34
MSR61 Investigating the Use of the Difference Method for Sampling More Than Two Ordered Variables	32
MSR177 Health-Related Quality-of-Life (HRQoL) Assessment for Japanese Cognitive Impairment Associated With Schizophrenia (CIAS)	31
HTA75 Payer Perceptions of Health Inequalities in Reimbursement Decision-Making: Results of a Global Survey	31
HTA246 Improving Access to Innovative Therapies for Rare Bleeding Disorders: Evidence From High Income Countries	30
MSR15 A Novel Crossover Adjustment Analysis of Overall Survival Results From the Phase 3 ClarIDHy Study of Ivosidenib Versus Placebo in Patients With MIDH1 Cholangiocarcinoma	30
MSR7 Superdeduper: Testing New AI-Powered System for Deduplicating References in Literature Reviews	30
PCR80 Barriers and Facilitators to the Recruitment and Engagement of Diverse Populations Into Patient Engagement Groups: A Scoping Review	29
PCR174 Importance of Specific Clinical Trial Enrollment Strategies for Native Hawaiian, Pacific Islander, and Asian Patients With Type 2 Diabetes Mellitus	29
MSR111 Using Patient-Level Simulation to Estimate Long-Term Survival in Idiopathic Pulmonary Fibrosis	28
PCR147 Treatment Preferences of Patients With Crohn's Disease in Greece: A Cross-Sectional Patient Survey	28
MSR125 AI-Powered Search Strategy Development and Optimization for Systematic Literature Reviews	27
EE307 Comparing Ancillary Services Associated With Subcutaneous Versus Intravenous Medication Administration	27
HTA308 Analysis of Factors Influencing the Assessment of Metastatic Solid Oncology Products in France: Central Role of Overall Survival (OS) Results and Other Parameters	27
EE393 Economic Impact of COVID-19 Vaccination Programs on Healthcare Workers: A Comparative Model-Based Analysis in the US, UK, Japan, and the Netherlands	27
SA97 The Relative Effectiveness & Safety of Fluocinolone Acetonide (FAc) and Dexamethasone (DEX) in Diabetic Macular Oedema: A Systematic Review and Matching Adjusted Indirect Treatment Comparison	27
Award Winners	27
EE375 An Early Health Economic Assessment on a New Method to Estimate 12-Hour Lithium Levels	27
HPR117 The Economic Burden of Lung Cancer in Greece: A Systematic Review of the Literature	26
EE362 Tirzepatide in the Treatment of Diabetes: A Systematic Overeview of Economic Evaluations	26
EE765 The Economic Burden of Mild Cognitive Impairment and Dementia Due to Alzheimer’s Disease in South Korea and Taiwan	26
EPH239 Positive Airway Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA): Modeling of 20 Year Mortality and Hospitalizations	26
EPH19 Ovarian Cancer Age-Adjusted Mortality Rates in Chile During 2002-2019	26
EE724 Healthcare Resources Utilization and Costs of Treatment Associated With Anogenital Warts in South Africa: Public and Private Perspective	26
EE840 Assessing Direct Medical Costs of Stage IV NSCLC in Iraq From Public Payer Perspective	24
P54 An Insight Into Real-World Evidence (RWE) As a Component of Submission to NICE & CADTH in the Last 3 Years	24
CO79 Effectiveness of Secukinumab in Patients With Moderate to Severe Hidradenitis Suppurativa: Results From a Meta-Analysis	24
EE830 Exploring Long-Term Durability Assumptions in Cost-Effectiveness Models of Cell and Gene Therapies: A Study of 39 Health Technology Assessments	24
EE178 The Burden of Multiple Myeloma in the Gulf Region	24
CO36 Placebo Effect for Clinical Remission in Induction and Maintenance Treatment in Crohn's Disease: A Systematic Literature Review and Meta-Analysis	24
EE198 Healthcare Resource Utilization (HCRU) by Patients With Duchenne Muscular Dystrophy (DMD) Using UK Patient Level Data	24
EE347 Cost-Effectiveness and Value-Based Price of High-Dose Quadrivalent Influenza Vaccine Among Elderly Populations in Taiwan	23
EE278 A Survey on Japanese Drug Pricing and Treatment Costs of Cancer Chemotherapy Drugs: The Case of Monoclonal Antibodies	23
EE396 Evaluating Long-Term Healthcare Resource Utilization in Biopsy-Confirmed MASLD: A Retrospective Longitudinal Observational Cohort Study in Sweden	23
EE306 Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses	23
EE527 Economic Evaluation of Using Romiplostim for Early Immune Thrombocytopenia in Qatar	22
CO142 Systematic Literature Review of Real-World Evidence on Overall Survival in Cancer Patients Before and After the Approval of Anti-PD-(L)1 Therapy	22
CO98 The Impact of Approved Anti-Obesity Medications on the Incidence of Osteoarthritis, Healthcare Resource Use and Costs Among Patients With Obesity: A Retrospective Cohort Study	22
CO146 Systematic Literature Review of Hospital Time and Resource Consumption in Subcutaneous and Intravenous Oncologic Biologic Therapies: The Case Study of Atezolizumab From an Italian Perspective	22
CO81 Pregabalin Utilization and Side Effects Among Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain in US Claims Data	22
MT60 Artificial Intelligence-Based Tools Designed to Predict Future Mechanical Ventilation and/or Mortality in Hospitalised COVID-19 Patients: A Systematic Literature Review	21
MT2 Real-World Evidence (RWE) in Action: A Review of Australia's Health Technology Assessment (HTA) of Non-Drug Health Technologies	21
SA95 A Pragmatic Data Extraction Approach for a Systematic Literature Review for Indirect Treatment Comparison Using Single-Arm Real-World Studies	21

SA27 A Non-Systematic Review Evaluating Search Strategies Leveraged in HTA Submissions to NICE	21
SA53 Epidemiology and Hospital Management of Patients With PROS in France	21
EE249 The Hidden Burden of Migraine: Analysis Using a Fiscal Framework in Colombia	21
RWD82 Economic Burden of Influenza and COVID-19 in French Hospitals: Analysis of PMSI Data From 2018 to 2022	20
RWD134 Healthcare Pathways and Therapeutic Outcomes of Patients With Spinal Muscular Atrophy: Results From the 12-Year Real-World Study EPI-SMA Based on the French National Healthcare Database (SNDS)	20
PCR89 Humanistic Burden of Adrenoleukodystrophy: A Systematic Review	20
PCR306 Exploring the Difference That Patient Involvement in HTA Makes in Cancer	20
PCR39 Health State Utility Values for Patients With Paroxysmal Nocturnal Hemoglobinuria Using EQ-5D-5L	20
PCR277 Patients’ Perspective of the Access to and Quality of Care for Chronic Kidney Disease: Insights From the DISCOVER-CKD Qualitative Study	20
RWD108 Unveiling the Burden and Impact of Flares in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real World Disease Specific Program in Europe	20
RWD157 A Real-World Study of Multiple Myeloma Patients With at Least 3 Prior Treatment Lines and Triple Class Exposed Disease in Finland: Outcomes and Need for Healthcare Resource Use	20
RWD88 The Psychosocial Impact of Chronic Hand Eczema: Findings From the Population-Based Check (Chronic Hand Eczema Epidemiology, Care, and Knowledge of Real-Life Burden) Study	19
RWD197 Literature Review on the Use of Synthetic Data and AI Advances for Patient-Centered, Sustainable HEOR	19
PT6 An “R-Shiny” Interface Designed As a One-Stop Solution for All Kinds of Survival Analysis According to NICE Technical Support Documents 14 and 21	19
PT37 Comparison of ICD-10 Diagnoses and Longitudinal Estimated Glomerular Filtration Rate (eGFR) in the Detection of Incident Stage 3 Chronic Kidney Disease (CKD): A Retrospective Comparison Study Usi	19
HSD125 Patient Pathways and Healthcare Resources Use in Hepatocellular Carcinoma: Full Analyses of the OPAL Study in Portuguese Population	18
PCR237 Patient Activation and Health Outcomes in Spinal Surgery: A Systematic Literature Review of Measures, Effects, and Strategies	18
MSR162 Identification of Patients With Obesity, Based on Their Comorbidities	18
CO139 Real-World Study of High-Risk Non-Muscle Invasive Bladder Cancer From Three Public Institutions in Mexico: Clinical Profile and Staging Patterns	18
HSD9 Development of a Framework for a Networked Service Model for the Care of Adults With Rare Bone Conditions: Healthcare Professional Survey for X-Linked Hypophosphataemia (XLH)	18
PCR192 Quality of Life and Its Drivers for Patients Living With Angelman Syndrome (AS): A Systematic Review	18
PCR96 Sociodemographic Variations in Perceived Social Support Among Adults with Depression in the United States: Results From the National Health and Wellness Survey	18
HTA63 Trends in Use of Cost-Minimization Analyses in CDA-AMC Reimbursement Submissions	18
RWD156 Patterns of Co-Medications Among People With Schizophrenia in Hong Kong	18
PCR211 Patient, Caregiver, and Physician Perspectives on the Burden of Disease Chronic Refractory Gout and Its Treatment: Concept Elicitation	18
HTA23 Broadening the Evidence Base: Incorporating Environmental Considerations Into HTAs	18
PCR210 Association Between Caregiver Quality of Life and the Care Provided to Adults With Severe Visual Impairments: A Systematic Literature Review	18
MSR71 Performance of AIC and BIC for the Extrapolation of Survival Data With Different Levels of Censoring	17
Strong Preferences or Simplifying Heuristics? Using Internal Validity Tests and Latent Class Analysis to Better Understand Stated Preference Survey Results. A Case Example in Health Preferences Resear	17
PCR169 Patient Involvement in Regulatory and HTA Processess: A Call for Enhanced Alignment	17
CO50 Analysis of Patient-Reported Outcomes of MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 12-Month Results from a Phase 2b Randomized, Sham-Controlled, Patient- and Assesso	17
PCR114 Mapping Health-Related Quality of Life (HRQoL) Measures to Preference Based Measures in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A systematic literature review	17
The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report	17
MSR41 The Use of Large Language Models for Systematic Literature Review Automation: An Evaluation of Quality and Time Savings	17
CO137 Are Standard Indirect Treatment Comparison Methods Suitable to Compare First-Line Vs Maintenance Therapies? An Assessment of Enfortumab Vedotin + Pembrolizumab Vs Avelumab in Locally Advanced/Me	16
EPH156 Multimorbidity and Its Associations with Adverse Cardiovascular Events and Healthcare Costs Among Patients with Atherosclerotic Cardiovascular Disease: A Real-World Evidence Study	16
CO67 Network Meta-Analysis to Compare the Efficacy Between Different Classes of PCSK9 Inhibitors, siRNA Vs. PCSK9 mAb, in Asian Patients With Hypercholesterolemia at Increased Cardiovascular Risk	16
Zero Dollar Copay Pharmacy Benefit Decreases Healthcare Expenditures Among Members With Type 2 Diabetes of Blue Cross Blue Shield of Louisiana	16
EE52 The Burden of Intravenous vs Subcutaneous Oncological Products Application in Honduras	16
EE181 Impact of Type 1 Diabetes on Productivity and Out-of-Pocket Costs of Adult Continuous Glucose Monitoring Users in the United States: Results From a Cross-Sectional Survey in the United States	16
CO107 Assessing Short and Long-Term Outcomes in Drug-Associated Acute Kidney Injury	16
MSR28 Use of Large Language Model (LLM) for Full-Text Screening in Systematic Literature Reviews: A Comparative Analysis	16
EE105 Cost-Effectiveness Analysis of Linperlisib for Relapsed or Refractory Follicular Lymphoma Based on Matching Adjusted Indirect Comparison in China	16
EPH190 Trends and Disparities in Perinatal Health Outcomes Among Women from Refugee Backgrounds in Victoria, Australia: A Population-Based Study	15
EE266 The Economics Promises of a Cure: Best Practices to Guide Economic Negotiations for the Reimbursement of Curative Therapies for Cancer	15
EE311 Exploring Environmental Impacts of Switching Salmeterol/Fluticasone Propionate (SAL/FP) from Metered Dose Inhaler (MDI) to Dry Powder Inhaler (DPI) in Respiratory Illness in the United Kingdom	15
EPH115 Sex Differences on Limitations in Physical Functioning and Overall Quality of Life of People Living with Myasthenia Gravis from the MGFA Global MG Patient Registry (MGFAPR) in the US	15
HPR38 Estimating the Outcome Disparities in BIPOC and Economically-Disadvantages Patients With Systemic Lupus Erythematosus (SLE)	15
EE226 Productivity Loss Among Persons With Multiple Sclerosis Treated With Ocrelizumab Vs Other Disease-Modifying Therapies	15
EE106 Cost-Effectiveness Analysis of Belimumab for the Treatment of Adults With Active Lupus Nephritis in China	15
EPH175 Assessment of Streptococcus Pneumoniae as Cause of Acute Otitis Media in Young Children in Colombia: A Prospective Study	15
EE258 Cost-Effectiveness of Transcatheter Aortic Valve Implantation (TAVI) for High-Risk Patients in Chile	15
HSD25 Patients’ Rare Disease Diagnoses and Their Impact on Physicians’ Emotions: A Cross-Sectional Study in the United States	15
PCR222 Comparison of Recanalisation Therapies in Terms of Quality of Life in Ischaemic Stroke Patients in Hungary	15
EE199 Budget Impact Analysis of the Anti-Vegfs Injections for Treating Diabetic Macular Oedema: Assessing Their Affordability in the UK Healthcare System	15
EE79 Real-World Clinical and Economic Burden of Primary Biliary Cholangitis in the United States	15
EE310 The Burden of Blood Transfusions Associated With Lower-Risk Myelodysplastic Syndromes (LR-MDS): Findings From a Survey of Health Care Professionals (HCPs) in Brazil, Germany, and Japan	15
EPH27 The Efficacy of Interventions Utilized in Communicating Risk Information to Improve Behavioral Outcomes Among Individuals Who Are Genetically Predisposed of Type 2 Diabetes: A Systematic Review	15
RWD135 Right-Sided vs Left-Sided Colorectal Cancer Hospitalization Outcomes in the US	15
PCR52 Early Real-World Experience With Abrilada Within the Canadian Patient Population	14
CO210 An Updated Systematic Review and Network Meta-Analysis on Risks of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis	14
PT4 Will the IRA's Negotiation Timelines Delay Access to Drugs for Orphan Indications?	14
P7 Costs and Health Care Resource Utilization Associated with Negative Symptoms Among Patients with Schizophrenia in the United States	14
CO72 Investigating Regional Differences in Cardiovascular Outcomes Among Patients Diagnosed with Hypertrophic Cardiomyopathy	14
EE438 A Budget Impact Model (BIM) for the Introduction of the TEARCARE® System to a United States (US) Health Plan for the Treatment of Meibomian Gland Dysfunction (MGD)-Associated Dry Eye Disease (DE	14
RWD174 Health Care Resources Associated with Clinical Pneumonia, Bacteremia or Meningitis in Colombian Adults: A Retrospective Database Study	14
PCR207 Health-Related Quality of Life and Its Associate Factors Among Residents in Tianjin, China: Findings from 2023 National Health Service Survey	14
EPH222 Trends of Mortality Related With Dengue in Colombia 2012-2021	14
SA13 Approaches to Electronic Health Records Notes Selection: Considerations for Best Practices	14
P20 Cardioprotective Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Early Breast Cancer Following Anthracycline- or Trastuzumab-Based Chemotherapy	14
EE45 Influential Factors on the Economic Justifiable Price: Systematic Investigation of Factors and Mechanisms Beyond the Incremental Cost Effectiveness Ratio	14
EPH14 Association between the Use of Macrolide Antibiotics and Recurrent Wheezing in Hospitalized Infants with Bronchiolitis	14
CO18 Impact of Empiric Treatment Failure on Healthcare Resource Utilization and Costs Among Females With Uncomplicated Urinary Tract Infections in a US-Based Integrated Health Delivery Network	14
P53 Validation of AI-Generated Synthetic Data for Outcomes Research: A Clinico-Genomics Case Study	14
SA48 Methods to Account for the Impact of COVID-19 in Real-World Retrospective Studies of Economic Outcomes: A Targeted Literature Review	14
EE481 Long-Term Cost-Effectiveness of Tirzepatide Versus Placebo for Individuals With Type 2 Diabetes and Obesity	14
CO49 Progression of Chronic Kidney Disease Among Older Adults with Hypertension Using Group-Based Trajectory Modeling	14
EE426 Cost-Comparison Analysis of Non-Invasive Testing Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Veteran Population	14
OP17 Are Dengue-Related Technological Solutions Evolving to Address the Global Public Health Problem?	13
HPR144 Optimization in Universal Health Coverage Design in South Africa Considering Both Health Outcomes and Health-Induced Poverty Outcomes	13

MSR45 Development and Validation of Machine Learning Algorithms to Predict 1-Year Ischemic Stroke and Bleeding Events in Patients With Atrial Fibrillation and Cancer	13
P26 VBA and R to Automate Health Economic Model Programming	13
PCR42 Health State Utilities in Duchenne Muscular Dystrophy (DMD): A Longitudinal Study Using the EQ5D and Health Utilities Index (HUI)	13
MT14 Assessing the Association Between Cardiovascular Acoustic Biomarkers and Heart Failure: A Systematic Literature Review	13
EPH211 Treatment Patterns and Clinical Characteristics of Patients Diagnosed with Metastatic NSCLC in Hmo from Colombia: A Real Word Evidence Study	13
SA11 Real-World Effectiveness and Safety of First-Line Pembrolizumab Monotherapy for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis	13
PCR41 Exploring the Landscape of Patient-Reported Outcomes in PCOS Clinical Trials	13
RWD50 Progression-Free Survival after First-Line Treatment in Endometrial Cancer Patients: A Real-World Perspective from Brazil and Argentina	13
SA76 A Targeted Literature Review of Economic Evaluations, Health-Related Quality of Life, Healthcare Resource Use, and Costs Associated With Polymyalgia Rheumatica	13
HTA56 ICER Vs NICE – What Are Your Key Considerations for Health Technology Assessments for Rare Disease Therapies? Insights from a Review of Completed Assessments (2017-PRESENT)	13
RWD141 Assessing the Potential Value of the Flatiron Health Commercial Mortality Data Combined with Publicly Available Death Data for Non-Oncology Research	13
MSR65 The Benefits of a Complex Identification and Stratification Model for Depression: Insights from a Large Claims Analysis Study	13
CO145 Utilizing Machine Learning to Predict Survival Outcomes in Multiple Myeloma Patients with Diabetes: Insights from a 20-Year Cohort Study	12
MSR101 Evaluating Pain Scores and Detecting NSCLC Using Named Entity Recognition and Agentic AI in Clinical Texts	12
MSR20 Discordance Between Two Claims-Based Frailty Indices in a Hospitalized Medicare Population	12
RWD106 Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US	12
RWD48 Impact of Circulating Tumor DNA (ctDNA) Burden Among Patients with Head and Neck Dquamous Cell Carcinoma (HNSCC) - A RWE Analysis	12
HPR119 Geographical and Temporal Variations in Availability of National Price Negotiated Novel Anticancer Drugs: A Spatial Statistical Study Based on Two Cross-Sectional Datasets in China	12
HTA59 Revisiting Archetypes: New Archetypes for Strategic Global Value Evidence Planning	12
EE176 Cost Savings with Treosulfan and Fludarabine Conditioning Regimen vs. RIC (Bu2/Flu and Flu/Mel) and MAC Regimens (Bu4/Flu and Bu4/Cy) in Patients Undergoing Allogeneic HSCT for AML or MDS	12
EE88 An Economic Model Exploring the Impact of Formulary Restrictions on the Incidence and Cost of Clinical Events in Patients with Non-Valvular Atrial Fibrillation Receiving Direct Oral Anticoagulant	12
RWD31 The Role of Real-World Evidence in Breast Cancer Drug Submissions to NICE: Insights and Challenges	12
RWD53 Burden of Illness and Healthcare Resource Utilization (HCRU) for Chronic Obstructive Pulmonary Disease (COPD) in Ontario, Canada	12
CO121 Analysis of the Burden of Illness, Treatment, and Health Disparities in Amyotrophic Lateral Sclerosis	12
RWD108 A1c Improvement After Initiating Real-Time Continuous Glucose Monitoring Among People with Type 2 Diabetes Not on Insulin Therapy	12
EE137 Work Productivity Losses of Systemic Lupus Erythematosus in a U.S. Commercially Insured Population	12
EPH10 Investigating the Pain Severity and Frequent Exercise Relationship in United States Adults Using the Medical Expenditure Panel Survey	12
HSD17 Co-Design of a Discrete Choice Experiment for Revascularization Decisions in Complex Coronary Heart Disease: Importance of Patient Perspectives	11
CO189 Patient- and Observer-Reported Outcomes with Therapeutic Medical Devices in Children and Adolescents with Obesity: A Systematic Literature Review	11
EE256 Cost-Utility Analysis of Lorlatinib in First-Line Treatment of adult patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (aNSCLC) in Colombia	11
EE303 The Time Value of Money driven by Early Disease-Modifying Interventions in Degenerative Disease	11
PT5 Disparities in Access to CAR-T treatments: Evidence from 100% Medicare Fee-For-Service and Medicare Advantage Claims Data	11
EE248 Healthcare Resource Utilization of Adult Patients with Obesity Before vs. After GLP-1 Treatment in the United States Elective Outpatient Setting	11
EE201 The Impact of Family Spillover Effects in Economic Evaluation for SMA Type 1 Treatments in the United States	11
EE104 Assessing the Economic Impact of Unused Medications in Acute Disease Management: A Retrospective Study in Algeria	11
EE411 Estimating the Potential Cost-Effectiveness of Long-Acting Naltrexone versus Oral Naltrexone for Alcohol Use Disorder	11
EE250 Quantifying Spillover Impacts: Effect of Novel Therapies for IgA Nephropathy on Patients Awaiting Kidney Transplant	11
HSD50 Racial/Ethnic Disparities in Veterans' Healthcare Experiences Across VA and Non-VA Settings: An Analysis of the Medical Expenditure Panel Survey (2018-2019)	11
MT31 Adoption of a Drug Adherence-Enhancing Application To Achieve Optimal Medication Adherence and Blood Pressure Control Among Hypertensive Patients: A Randomized Controlled Trial	11
CO119 Bridging the Gap between the NAPOLI 3 Trial and Real-World Practice: Real-World Overall Survival (OS) of First-Line (1L) FOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	11
HSD41 Impact of Racial and Ethnic Disparities on Health-Related Quality of Life in Older Adults With Arthritis in the United States	11
RWD80 Presenteeism in Employees with Chronic Conditions: An Analysis Using Linked Claims and Self-Reported Employee Health Risk Assessment Data	11
EE165 Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System	11
HSD52 Understanding Barriers to the Early Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease from the Perspective of Physicians and Patients: Results from a Real-World Survey in Germany	11
CO21 Real-World Evidence on Clinical Outcomes and Safety of Trastuzumab Biosimilar in Colombian Breast Cancer Patients	11
HSD96 Conceptualisation and the Role of Market Access in Pharmaceutical Industry: A Qualitative Study	11
Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life	10
CO86 Comparing Chemotherapy, Monotherapy, and Combination Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer Progression-Free Survival and Overall Survival: Systematic Review and Meta-Analysi	10
PCR101 Association of Chronic Conditions and Medication Burden with Patient Preferences for Long-Acting Antiretroviral Therapy in HIV Treatment	10
POSC161 Cost-Consequence Analysis of Rosuvastatin Versus Atorvastatin in the Spanish Setting	10
POSA373 Evaluation of Ehealth Literacy Measurement Tools and Its Associated Factors: A Systematic Review and Meta-Analysis	10
How Do Patients Value the Benefit of Minimally Invasive Surgery in Cancer Treatment?	10
Exploring the Comparability Between EQ-5D and the EQ Health and Wellbeing in the General Australian Population	10
MSR165 Evaluating the Effectiveness of AI-Generated vs Real Abstracts in Training Machine Learning Models for Study Selection in Systematic Literature Reviews	10
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force	10
Disinvestment and Health Spending Efficiency in Latin America and the Caribbean: A Case Study of Colombia	10
POSB42 The Health-Economic Evaluation of Risdiplam in Patients with Spinal Muscular Atrophy	10
POSB55 Economic Consequences of Anti-HCV Treatment of Patients Diagnosed through Screening in Italy: A Prospective Modelling Analysis	10
MSR72 An Evaluation of the Rayyan Artificial Intelligence Tool for Systematic Literature Review Screening	10
A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children With Asthma	10
SA24 CHIME2 (Chinese Hong Kong Integrated Modeling and Evaluation): An Updated Model to Simulate Lifetime Health Outcomes of Patients with Type 2 Diabetes	10
POSA371 Barriers and Expectations for Patients in Post-Osteoporotic Fractures Care in France: The Effel Study	10
POSB62 Budget Impact Analysis of Ertugliflozin Inclusion in the List of Vital and Essential Medicines in Russian Federation	10
EE115 Markov Simulation for Estimating the Impact of Lecanemab Treatment on Health Outcomes in Early Alzheimer's Disease from a Japanese Societal Perspective	10
HSD101 Lack of concordance between real-world treatment patterns and clinical guideline recommendations for metastatic hormone-sensitive prostate cancer (mhspc) patients	9
Table of Contents	9
Modeling the Recovery of Elective Waiting Lists Following COVID-19: Scenario Projections for England	9
HTA35 Testing and Piloting of a Value Framework for Diagnostic Technologies in Latin America	9
RWD120 Impact of Healthcare Fragmentation on Survival of Patients with Colorectal Cancer in Colombia	9
EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database	9
P32 Power Implications of Estimator Choice in Synthetic Control Arm Analyses: Results from a Simulation Comparing Average Treatment Effects on the Treated and Untreated Under Propensity Score Weightin	9
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing	9
A Systematic Review of International Guidance for Self-Report and Proxy Completion of Child-Specific Utility Instruments	9
HSD129 Managing Members with Complex Conditions: A Blue Cross and Blue Shield of Louisiana Program Evaluation	9
EE467 Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital	9
EE498 Economic Burden of Interstitial Lung Disease in a Commercially Insured Population with Sjogren's Syndrome in the United States	9
RWD86 Healthcare Resource Utilization and Economic Burden of Patients with Gout in the United States	9
RWD48 Inpatient Resource Utilization Outcomes Among Patients Living with Fragile X Syndrome and Comorbid Autism Spectrum Disorder in the US	9
Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare	9
Editorial Board	9
RWD118 Rapid Diversification of Immune Checkpoint Inhibitor Usage in Community Health Systems in the US Following New Drug Approvals	9
RWD116 Reduced Lysosomal Acid Lipase Activity in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Current Evidence and Future Directions	9
HTA49 Determining Appropriate Health Economic Modeling Approaches in Fabry Disease	9
PCR101 Item Response Theory Analysis of the Ilqi	8
EE308 Real-World Treatment Patterns and Costs in Relapsed and Refractory Diffuse Large B-Cell Lymphoma in the United States	8
EE154 Burden of Invasive Extraintestinal Pathogenic E. coli Disease Among Older Adult Patients Treated in Hospitals in the US	8
EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective	8
EPH69 Cancers Treatment from Their Perspective: A Qualitative Pilot Study Exploring the Knowledge Attitude and Practice of Folk Medicine Practitioners in a Low-and-Middle-Income-Country	8
EE302 Households Out-of-Pocket Healthcare Expenditures Based on Number of Chronic Conditions in Riyadh, Saudi Arabia: A Quantile Regression Approach	8
EE139 Using a User-Friendly Modeling Tool to Inform and Guide Local Decision-Making for Lynch Syndrome Screening at Healthcare Systems	8
EPH67 Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee "Caregivers” of Patients with Breast, Skin, GI, Female, Male, and "Other” Cancers	8
PCR102 Leveraging Social Media for Patient Experience Insights in Rare Disease	8
CO87 Treatment Patterns and Costs Associated with Small Cell Lung Cancer in a U.S. Medicare Population	8
EE315 Economic Evaluation of Neutralising Monoclonal Antibodies for the Treatment of COVID-19 Positive People in the Community	8
PCR128 Rapid Review: Were There Any Clinical Trials in Non-Muscle Invasive Bladder Cancer That Naturally Adopted the Updated FDA COA Oncology Guidance?	8